Background And Aim: Serum pepsinogen I (PGI) and pepsinogen II (PGII) are noninvasive parameters in the detection of atrophic gastritis. The diagnostic add-on value of serum gastrin-17 (G-17) remains uncertain. The aim of this study was to assess the stability of these serum parameters over time and to evaluate the influence of clinical factors, such as upper gastrointestinal (GI) endoscopy and bowel cleansing, on serum PGI, PGII, and G-17 assessment.
Patients And Methods: A prospective study was carried out in healthy individuals and patients. For the stability analyses, the plasma and serum samples from 23 individuals were processed at different time points with and without the addition of a stabilizer. Ten patients were included to evaluate the influence of upper GI endoscopy and 18 patients to evaluate the effect of bowel cleansing before colonoscopy.
Results: PGI, PGII, and G-17 levels were not statistically different in the serum and plasma. PGI and PGII serum levels were stable over time. G-17 is associated with time-dependent degradation (P=0.0001). The addition of the G-17 stabilizer showed no improvement in stability. Upper GI endoscopy and bowel preparation before colonoscopy were associated with minimal variations in PGI and PGII, whereas G-17 showed patient-specific alterations.
Conclusion: PGI and PGII serum levels are stable over time. However, G-17 stability is strongly dependent on the time of processing and storage; therefore, samples for G-17 analysis need to be processed no later than 6 h after blood collection. Upper GI endoscopy and colonoscopy preparation lead to minimal nonsignificant changes in basal PGI, PGII, and G-17 levels.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MEG.0000000000000952 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Safety and efficacy of Relatox in comparison with Dysport in the treatment of focal spasticity of the upper limb in patients after stroke and traumatic brain injury (results of a prospective simple blind randomized comparative study in parallel groups)].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
GUTA-CLINIC LLC, Moscow, Russia.
Objective: Evaluation of the safety and effectiveness of Relatox, botulinum toxin type A in patients with focal spasticity (FS) of the upper limb as a result of a cerebrovascular accident (CVA) or traumatic brain injury (TBI).
Material And Methods: A multicenter, prospective, single-blinded, randomized, comparative clinical study included 210 patients of both sexes aged 18-75 years after moderate to severe TBI and CVA in seven sites in the Russian Federation. The patients were randomized into two groups.
The Effect of Anterior Colporrhaphy: A Prospective Study Comparing POP-Q and Upright MRI.
Int Urogynecol J
December 2024
Department of Gynecology, Ziekenhuisgroep Twente, Hengelo, The Netherlands.
Introduction And Hypothesis: The high recurrence rate (up to 40%) of native tissue surgery for pelvic organ prolapse (POP) is concerning and a better understanding of the effect of surgery is essential in optimizing treatment. As physical examination (Pelvic Organ Prolapse-Quantification, POP-Q) underestimates the degree of prolapse, upright assessment may provide new insights. Therefore, we compared supine POP-Q with upright magnetic resonance imaging (MRI) examination of the anatomical effect of native tissue POP surgery on the pelvic anatomy.
View Article and Find Full Text PDFEfficacy and safety of galcanezumab for cluster headache preventive treatment: a systematic review and meta-analysis.
Neurol Res
January 2025
Neurology, Division of General Neurology and Headache, University of Rochester, Rochester, NY, USA.
Article Synopsis
- Galcanezumab is a monoclonal antibody that targets the CGRP pathway, representing a new treatment option for cluster headaches (CH).
- A systematic review and meta-analysis of six studies, involving 504 patients, evaluated the drug's effectiveness and safety, finding a significant reduction in CH attack frequency in 76% of participants.
- While 48% of patients experienced treatment-emergent adverse events, the side effects were notably higher in those taking the 300 mg dose compared to the 240 mg dose, suggesting galcanezumab is generally effective and safe for managing CH.
Is Intravesical Gentamicin the New Gold Standard to Manage Refractory Urinary Tract Infections?-Experience From a Dedicated Multidisciplinary Complex UTI Clinic.
Neurourol Urodyn
December 2024
Department of Urology, James Cook University Hospital, Middlesbrough, UK.
Aims: To assess the effectiveness of intravesical gentamicin in managing recurrent urinary tract infections (rUTIs) refractory to first- and second-line treatments.
Methods And Materials: This single-centre prospective cohort study included 41 patients treated with intravesical gentamicin over a 24-month period from 2021 to 2023. A multidisciplinary team comprising functional urologists, microbiologists, and specialist nurses was involved in the decision-making process and in designing the treatment protocol.
LeFort Colpocleisis: Unmet Expectations about Correction of Urinary Symptoms Are Related to Disappointment and Regret.
J Midlife Health
October 2024
1 Department of Obstetrics and Gynecoloogy, Papageorgiou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Article Synopsis
- The study aimed to evaluate the long-term outcomes, satisfaction, and reasons for disappointment in patients with advanced pelvic organ prolapse who underwent LeFort colpocleisis (LFC).
- Conducted between 2007 and 2021, the study included 141 patients and used surveys to assess their health and satisfaction 61.65 months after surgery.
- Results indicated a low rate of prolapse recurrence and no regrets about sexual function loss; however, persistent urinary incontinence correlated with decreased satisfaction and regret.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!